

INDEX TO VOLUME 15

AUTHOR INDEX

- Agarwal, N., 285
 Ahluwalia, B.S., 465
 Alapiessa, U., 1
 Alvarez-Sanchez, F., 635
 Anderson, J.E., 705
 Archer, R.D., 93
 Åstedt, B., 711
 Atienza, M.F., 435
 Atkinson, L.E., 335
 Avila, T.D., 307
 Bahgat, M.R., 335
 Balog, J., 553
 Bartsch, G., 649, 669
 Basu, R., 429
 Benagiano, G., 513
 Bergström, S., 129
 Bernstein, G.S., 679
 Bhuyan, U.N., 39
 Birk, S.A., 65
 Boeckx, W.D., 505
 Boettcher, B., 163
 Brache, V., 635
 Brenner, P.F., 679
 Brosens, I.A., 505
 Bueno, M., 225
 Buhi, W.C., 65
 Burkman, R.T., 435
 Bygdeman, M., 129
 Carraher, R.P., 15
 Chantler, E.M., 543
 Chatterjee, A., 429, 571
 Chaudhuri, G., 589
 Chvapil, M., 693
 Chvapil, T., 693
 Cooper, D.L., 75
 Coutinho, E.M., 627
 Crocker, C.L., 465
 Czernobilsky, B., 183
 Daunter, B., 543
 David, A., 183
 De Muylder, E., 717
 Dequeker, J., 717
 de Ridder, U., 319
 Diczfalusy, E., 513
 Dogs, G., 579
 Elder, M.G., 589
 Elstein, M., 543
 Faundes, A., 635
 Ferin, J., 717
 Filho, F.N., 563
 Findlay, J.K., 53
 Frick, J., 649, 669
 Fylling, P., 347
 Ganguli, A., 129
 Garcia, C.-R., 445
 Gaton, E., 183
 Gesche, M., 705
 Ginsberg, A.P., 93
 Goldzieher, J.W., 255, 513
 Gordon, D., 589
 Gray, R., 513
 Green, K., 129
 Greer, L., 465
 Griffiths, K., 473
 Gupta, T., 571
 Haspels, A.A., 105
 Heine, M.W., 693
 Helton, E.D., 255
 Hillier, S.G., 473
 Hingorani, V., 39, 285
 Holma, P.K., 151
 Hooley, R.D., 53
 Horton, H.L., 693
 Huggins, G.R., 445
 Hümpel, M., 401, 413, 579
 Hyne, R.V., 163
 Jacobs, S., 693
 Jerve, F., 347
 Jeyaseelan, S., 39
 Jha, P., 473
 Johansson, E.D.B., 413
 Joshi, J., 327
 Kamboj, V.P., 601
 Kaplun, A., 183
 Karlsson, K., 711
 Khanna, K.L., 465
 Khanna, N.M., 601
 Kicovic, P.M., 105
 Kimmel, H.B., 25
 King, T.M., 435
 Kinoshita, K., 129
 Kora, S., 327
 Kühne, G., 401
 Kulkarni, B.D., 307
 Lähteenmäki, P., 389
 Langhauser, C., 553

CONTRACEPTION

INDEX TO VOLUME 15

AUTHOR INDEX (CONTINUED)

- | | |
|------------------------------|-----------------------------|
| Larsson, B., 143, 711 | Rickels, K., 445 |
| Laumas, K.R., 39, 285, 473 | Rosencwaig, A., 93 |
| Lawson, J., 355 | Rosenfeld, D.L., 445 |
| Leon, P., 635 | Ruelius, H.W., 25 |
| Lewis, K.M., 93 | Saraya, L.K., 285 |
| Liedholm, P., 215, 711 | Sartoretto, J.N., 563 |
| Linthorst, G.A., 105 | Schmidt-Gollwitzer, M., 197 |
| Liu, A.L., 25 | Schneider, W.H.F., 413 |
| Loewit, K., 233 | Schulze, P.-E., 401, 579 |
| Lundström, V., 129 | Setty, B.S., 601 |
| Luukkainen, T., 295 | Sheth, A.R., 327 |
| McLeod, M., 355 | Sisenwine, S.F., 25 |
| McNellis, D., 355 | Sjöberg, N.-O., 215 |
| Mehta, S., 327 | Skryten, A., 711 |
| Melo, J.F., 627 | Speck, U., 401, 579 |
| Mishell, D.R., Jr., 679 | Spellacy, W.N., 65 |
| Moraes, R., 563 | Spona, J., 413 |
| Morris, L., 705 | Stohs, S.J., 535 |
| Myatt, L., 589 | Stubblefield, P.G., 175 |
| Nevinny-Stickel, J., 197 | Takkar, D., 39 |
| Nieuweboer, B., 413 | Tonascia, J.A., 435 |
| Nilsson, C.G., 295, 379, 389 | van Bogaert, L.J., 319 |
| Nilsson, S., 87 | van der Pas, H., 319 |
| Nygren, K.-G., 87 | Vasquez, G., 505 |
| O'Leary, J.A., 307 | Verma, P.S., 465 |
| Ortega-Recio, J.C., 563 | Victor, A., 87 |
| Ortiz, A., 679 | Virkar, K.D., 327 |
| Owen, J.A., 693 | Weiner, E., 413 |
| Pal, A.K., 429, 571 | Weiske, W.-H., 649, 669 |
| Pasquale, S.A., 355 | Weiss, C., 579 |
| Pawar, V., 327 | Wendt, H., 579 |
| Puri, C.P., 285 | Wennergren, M., 143 |
| Rådberg, T., 711 | Widholm, O., 1 |
| Raikar, R.S., 327 | Williams, D.M., 53 |
| Rajani, U., 327 | Yuliano, S.E., 355 |
| Ray, P., 429 | Zoremthangi, B., 285 |
| Reinke, L.A., 535 | |
| Rhine, I., 553 | |

INDEX TO VOLUME 15

SUBJECT INDEX

- Ablactating steroids, effect on first postpartum ovulation, 319
- Abortion,
 - contraceptive practice before and after, 347
 - first trimester, 15(S) 15 methyl $\text{PGF}_{2\alpha}$ methyl ester vaginal suppositories for dilatation of cervix, 285
 - immediate post-abortion insertion of IUD and risk for endometritis, 435
 - immediately after, plasma levels of d-norgestrel and SHGB during d-norgestrel medication, 87
 - second trimester, 15(S)-15 methyl $\text{PGF}_{2\alpha}$ methyl ester, vaginal silastic device, 175
 - vaginal suppository for single administration, 15-methyl $\text{PGF}_{2\alpha}$ methyl ester, 129
- Anabolic steroid, metandienone, effect on spermatogenesis, 151
- Antibody, sperm immobilizing (rabbit), 15
- Antifertility faculty of PMSG, reversal by clomiphene citrate or reserpine (rat), 571
- Attainment of azoospermia, medroxyprogesterone acetate and testosterone enanthate, 635
- Azoospermia, attainment and maintenance with medroxyprogesterone acetate and testosterone enanthate, 635
- Binding of steroids by spermatozoa, 163
- Bioavailability, cyproterone acetate and ethinyloestradiol combination, 579
- Biological effects, modified sequential oral contraceptive, 1
- Bone mass, effect of long-term lynestrenol treatment, 717
- Caffeine blood level, hypertensive oral contraceptive users, 465
- Carbohydrate metabolism, effect of progesterone-T IUD, 65
- Cervical mucus, levels of trace metals, sulphydryl and disulphide groups, 543
- Cervicovaginal secretion, sperm immobilizing antibody (rabbit), 15
- Chemical composition, copper IUD corrosion layer, 93
- Clinical evaluation, norethisterone oenanthate and medroxyprogesterone acetate, 513
- Clinical study, low dose estrogen-progesterone combination, 563
- Clinical testing, intravaginal contraceptive collagen sponge, 693
- Clomiphene citrate, reversal of PMSG antifertility faculty (rat), 571
- Coagulating property on semen, Indian medicinal plants, 601
- Collagen sponge, intravaginal contraceptive, laboratory and clinical testing, 693
- Combination oral contraceptive,
 - cyproterone acetate and ethinyloestradiol, bioavailability and pharmacokinetics, 579

CONTRACEPTION

- Combination oral contraceptive,
 - low dose d-norgestrel and ethinyl estradiol, clinical study, 563
- Comparative clinical evaluation, multinational, injectable norethisterone oenanthate and medroxyprogesterone acetate, 513
- Conception for pregnancies resulting in unwanted births, contraceptive use at the time, 705
- Contraceptive methods, recent trends in preference, 553
- Contraceptive practice, before and after termination of pregnancy, 347
- Contraceptive use at time of conception for unwanted births, 705
- Contraceptive users, oral, cure rates for vulvovaginal candidiasis, 355
- Copper, level in cervical mucus, 543
- Copper 7 and copper T IUD, modified insertion techniques, 75
- Copper IUD,
 - corrosion chemistry, 93
 - Cu-7, levels of trace metals, sulphhydryl and disulphide groups in cervical mucus, 543
 - effect on frequency and healing of pelvic inflammatory disease, 143
 - effect on prolactin levels, 327
 - fibrinolytic activity in uterus and its fluid (rabbit), 215
 - fibrinolytic activity of endometrium in diabetic women, 711
 - Nova-T-copper device, menstrual blood loss, 379
- Corpus luteum function,
 - effect of a morning after injection, 105
 - effect of steroids (sheep), 53
- Corrosion chemistry, copper IUDs, 93
- Culdospeculum, use in interval vaginal tubal ligation, 225
- Cyproterone acetate (17-acetoxy-6-chloro-1 α ,2 α -methylene-4,6,-pregnadiene-3,20-dione)
- Cyproterone acetate, effect on sperm fertility (rat), 429
- Cyproterone acetate and ethinyloestradiol combination,
 - bioavailability and pharmacokinetics, 579
- Delivery, immediately after, plasma levels of d-norgestrel and SHBG during d-norgestrel medication, 87
- Depot contraceptive, injectable d-norgestrel, 413
- Depot contraceptives, injectable d-norgestrel (dog, baboon), 401
- Diabetic women using Cu-IUDs, fibrinolytic activity of endometrium, 711
- Diaphragm, recent trends in preference of contraceptive methods, 553
- Diethylstilbesterol, medical and social factors of post-coital contraception, 445

- Dilatation of cervix, 15(S) 15 methyl PGF₂α methyl ester vaginal suppositories, 285
- Disulphide group, level in cervical mucus, 543
- Endometritis risk, immediate post-abortion IUD insertion, 435
- Endometrium,
 - effect of a morning after injection, 105
 - fibrinolytic activity in diabetic women using Cu-IUDs, 711
 - histochemistry of regeneration with IUD (rabbit), 183
- Epididymal spermatozoa, effect of cyproterone acetate (rat), 429
- Equilenin, effect on corpus luteum function (sheep), 53
- Estradiol benzoate and estradiol phenylpropionate, effect as a morning after injection, 105
- Estriol, effect on corpus luteum function (sheep), 53
- Estrogens,
 - serum concentration, subdermal implants of R-2323 (monkey), 335
 - synthetic, metabolic fate after exposure to oral contraceptives (baboon), 307
- Ethinyl estradiol and d-norgestrel combination, low dose, clinical study, 563
- Ethinyl estradiol, metabolic fate after exposure to oral contraceptives (baboon), 307
- Ethynylestradiol blood level, hypertensive oral contraceptive users, 465
- Ethinyl estrogens,
 - absorption from gastrointestinal tract, 255
 - conversion of mestranol to ethynylestradiol, 255
 - excretion, 255
 - isolation and identification of conjugated metabolites, 255
 - isolation and identification of free metabolites, 255
 - oxidative metabolism and covalent binding, 255
 - plasma levels, 255
 - plasma protein binding, 255
 - review of pharmacokinetics, 255
 - tissue distribution, 255
- Fibrinolytic activity in uterus and its fluid with copper IUD (rabbit), 215
- Fibrinolytic activity of endometrium, diabetic women using Cu-IUDs, 711
- First trimester abortion, 15(S) 15 methyl PGF₂α methyl ester vaginal suppositories for dilatation of cervix, 285
- Fluid, uterine, fibrinolytic activity with copper IUD (rabbit), 215
- Foam, recent trends in preference of contraceptive methods, 553
- Frequency of pelvic inflammatory disease, effect of copper IUD, 143
- Gonadotropins, serum profile during treatment with lynestrenol, 197

CONTRACEPTION

- Healing of pelvic inflammatory disease, effect of copper IUD, 143
- Hepatic mixed function monooxygenase enzymes, effect of vasectomy (rat), 535
- High initial dose, effect of medroxyprogesterone acetate and testosterone enanthate on spermatogenesis, 669
- Histochemistry of regenerating endometrium with IUD (rabbit), 183
- Hydroxypropylmethylcellulose, spermicidal effect, 233
- Hypertensive oral contraceptive user, caffeine and ethynyl-estradiol levels, 465
- Immobilization of spermatozoa, effect of hydroxypropylmethylcellulose, 233
- Immobilizing antibody, induction and activity (rabbit), 15
- Induction of sperm immobilizing antibody (rabbit), 15
- Injectable contraceptives, norethisterone oenanthate and medroxyprogesterone acetate, 513
- Injectable depot contraceptive, d-norgestrel, 413
- Injectable depot contraceptives, d-norgestrel (dog, baboon), 401
- Injections of medroxyprogesterone acetate and testosterone enanthate,
 - attainment and maintenance of azoospermia, 635
 - effect on spermatogenesis, 627, 649, 669
 - male contraceptive, 679
- Injections of medroxyprogesterone acetate and testosterone propionate implant, effect on spermatogenesis, 649
- Insertion techniques for IUDs, modified method, 75
- Interval vaginal tubal ligation with use of the Culdo-speculum, 225
- Intravaginal contraceptive collagen sponge, laboratory and clinical testing, 693
- Intravaginal contraception, semen coagulating property of Indian medicinal plants, 601
- Iron, level in cervical mucus, 543
- IUD,
 - containing d-norgestrel, 295
 - copper,
 - corrosion chemistry, 93
 - effect on frequency and healing of pelvic inflammatory disease, 143
 - effect on prolactin levels, 327
 - fibrinolytic activity in uterus and its fluid (rabbit), 215
 - fibrinolytic activity of endometrium in diabetic women, 711
 - Cu-7, levels of trace metals, sulphhydryl and disulphide groups in cervical mucus, 543
 - histochemistry of regenerating endometrium (rabbit), 183
 - immediate post-abortion insertion and risk for endometritis, 435

- IUD,
 - menstrual blood loss, d-norgestrel-releasing IUD, 379
 - menstrual blood loss, Nova-T-copper IUD, 379
 - modified insertion techniques, 75
 - d-norgestrel-releasing IUD, recovery of ovarian function, 389
 - progesterone-T, effect on carbohydrate and lipid metabolism, 65
 - prostaglandin production by attached leucocytes, 589
 - recent-trends in preference of contraceptive methods, 553
- Laboratory testing, intravaginal contraceptive collagen sponge, 693
- Leucocytes attached to IUD, prostaglandin production, 589
- Lipid metabolism, effect of progesterone-T IUD, 65
- Local tissue response, silastic implant containing norethindrone, 39
- Long-acting injectable contraceptives, norethisterone oenanthate and medroxyprogesterone acetate, 513
- Long-term contraception, silastic implant releasing norethindrone acetate, 473
- Long-term lynestrenol treatment, effect on bone mass, 717
- Los dose estrogen-progestogen combination, clinical study, 563
- LRH (luteinizing hormone releasing hormone)
- LRH-stimulation test, during use of d-norgestrel-releasing IUD, 389
- Luteinizing hormone releasing hormone (LRH)
- Lynestrenol,
 - long-term use, effect on bone mass, 717
 - serum profile of gonadotropins and ovarian steroids during treatment, 197
- Maintenance of azoospermia, medroxyprogesterone acetate and testosterone enanthate, 635
- Male contraception, medroxyprogesterone acetate and testosterone enanthate, 627, 635, 649, 669, 679
- Male contraception, medroxyprogesterone acetate and testosterone propionate, 649
- Male contraceptive, effect of metandienone, 151
- Manganese, level in cervical mucus, 543
- Medical factors, post-coital contraceptive users, 445
- Medroxyprogesterone acetate and norethisterone oenanthate, comparative clinical evaluation, 513
- Medroxyprogesterone acetate and testosterone enanthate, attainment and maintenance of azoospermia, 635
- effect on spermatogenesis, high initial dose, 669
- effect on spermatogenesis, uniform dosage level, 649
- inhibition of spermatogenesis, 627
- male contraceptive, 679
- Medroxyprogesterone acetate and testosterone propionate, effect on spermatogenesis, uniform dosage level, 649

CONTRACEPTION

- Megestrol acetate, effect on corpus luteum function (sheep), 53
- Menstrual blood loss,
d-norgestrel-releasing IUD, 379
Nova-T-copper IUD, 379
- Mestranol, metabolic fate after exposure to oral contraceptives (baboon), 307
- Metabolic fate of synthetic estrogens, after exposure to oral contraceptives (baboon), 307
- Metabolites of d-norgestrel-3-oxime-17-acetate (monkey), 25
- Metandienone (17 α -methyl-17 β -hydroxy-1,4-androstadien-3-one)
Metandienone, effect on spermatogenesis, 151
- 15-Methyl PGF₂ α methyl ester, single vaginal suppository for interruption of pregnancy, 129
- Miconazole nitrate 2% vaginal cream, cure rates for oral contraceptive users and non-users treated for vulvovaginal candidiasis, 355
- Morning after injection, effect on corpus luteum function and endometrium, 105
- Morning after pill, medical and social factors, 445
- Multinational comparative clinical evaluation, injectable norethisterone oenanthate and medroxyprogesterone acetate, 513
- Norethindrone,
effect on corpus luteum function (sheep), 53
local tissue response to silastic implant, 39
radioimmunoassay, 473
- Norethindrone acetate, silastic implant, serum concentration of norethindrone, 473
- Norethisterone oenanthate and medroxyprogesterone acetate, comparative clinical evaluation, 513
- d-Norgestrel,
conversion from d-norgestrel-3-oxime-17-acetate (monkey), 25
effect on corpus luteum function (sheep), 53
injectable depot contraceptive, 413
injectable depot contraceptives (dog, baboon), 401
radioimmunoassay, 413
- d-Norgestrel-3-oxime-17-acetate, conversion to d-norgestrel (monkey), 25
- d-Norgestrel-releasing IUD, 295
menstrual blood loss, 379
recovery of ovarian function, 389
- d-Norgestrel and ethinyl estradiol combination, low dose, clinical study, 563
- d-Norgestrel medication, plasma levels of d-norgestrel and SHBG after delivery or abortion, 87
- Normophasic oral contraceptive, biological effects, 1

- Oral contraceptive,
 - cyproterone acetate and ethinyloestradiol combination, bioavailability and pharmacokinetics, 579
 - hypertensive users, caffeine and ethynylestradiol levels, 465
 - low dose d-norgestrel and ethinyl estradiol combination, clinical study, 563
 - lynestrenol, serum profile of gonadotropins and ovarian steroids, 197
 - metabolic fate of synthetic estrogens after exposure to oral contraceptives (baboon), 307
 - modified sequential, biological effects, 1
 - recent trends in preference of contraceptive methods, 553
- Oral contraceptive users and non-users, cure rates for vulvo-vaginal candidiasis, 355
- Ovarian function, recovery after use of d-norgestrel-releasing IUD, 389
- Ovarian steroids, serum profile during treatment with lynestrenol, 197
- Ovulation, first postpartum, effect of treatment with ablactating steroids, 319
- Pelvic inflammatory disease, effect of copper IUD, 143
- PGF₂ α (prostaglandin F₂ α)
- Pharmacokinetic studies, injectable depot d-norgestrel contraceptives (dog, baboon), 401
- Pharmacokinetic study, injectable depot d-norgestrel contraceptive, 413
- Pharmacokinetics, cyproterone acetate and ethinyloestradiol combination, 579
- Pharmacokinetics of ethinyl estrogens, review, 255
- Plants, semen coagulating property of Indian medicinal plants, 601
- PMSG (pregnant mare's serum gonadotrophin)
- PMSG, effect of clomiphene citrate or reserpine on anti-fertility faculty (rat), 571
- Post-abortion IUD insertion, risk for endometritis, 435
- Post-coital contraception, medical and social factors, 445
- Postcoital therapy, effect of a morning after injection, 105
- Postpartum ovulation, first, effect of treatment with ablactating steroids, 319
- Preference of contraceptive methods, recent trends, 553
- Pregnancies resulting in unwanted births, contraceptive use at time of conception, 705
- Pregnant mare's serum gonadotrophin (PMSG)
- Progesterone, serum concentration, subdermal implants of R-2323 (monkey), 335
- Progesterone-T IUD,
 - effect on carbohydrate and lipid metabolism, 65
 - modified insertion technique, 75
- Prolactin level, effect of copper IUDs, 327
- Prostaglandin,
 - 15(S)-15 methyl PGF₂ α methyl ester, vaginal silastic device for second trimester abortion, 175

CONTRACEPTION

- Prostaglandin,
15(S) 15 methyl $\text{PGF}_2\alpha$ methyl ester, vaginal suppository
for dilatation of cervix, 285
single 15-methyl $\text{PGF}_2\alpha$ methyl ester vaginal suppository
for interruption of pregnancy, 129
- Prostaglandin $\text{F}_2\alpha$ ($\text{PGF}_2\alpha$)
Prostaglandin production by leucocytes attached to IUDs, 589
R-2323 (13 β -ethyl-17 α -ethynyl-17 β -hydroxy-gona-4,9(10), 11-
triene-3-one)
effect on corpus luteum function (sheep), 53
serum concentration, subdermal implants of R-2323
(monkey), 335
subdermal implants (monkey), 335
serum concentration of estrogens, 335
serum concentration of progesterone, 335
serum concentration of R-2323, 335
- R-5020 (17 α -21-dimethyl-19-nor-pregna-4,9(10)-diene-3,20-dione)
effect on corpus luteum function (sheep), 53
- Radioimmunoassay,
norethindrone, 473
d-norgestrel, 413
- Recovery of ovarian function after use of d-norgestrel-
releasing IUD, 389
- Regeneration of endometrium with IUD, histochemical investiga-
tion (rabbit), 183
- Reserpine, reversal of PMSG antifertility faculty (rat), 571
- Reversibility of tubal ring sterilization (rabbit), 505
- 15(S) 15 methyl $\text{PGF}_2\alpha$ methyl ester, vaginal suppository
for dilatation of cervix, 285
- Second trimester abortion, vaginal silastic device containing
15(S)-15 methyl $\text{PGF}_2\alpha$ methyl ester, 175
- Second trimester pregnancy interruption, single 15-methyl
 $\text{PGF}_2\alpha$ methyl ester vaginal suppository, 129
- Selective binding of steroids by spermatozoa, 163
- Semen, coagulating property of Indian medicinal plants, 601
- Sequential oral contraceptive, biological effects, 1
- SHBG (sex hormone binding globulin)
- SHBG and d-norgestrel, plasma levels after delivery or
abortion, 87
- Silastic capsules containing R-2323, subdermal implants
(monkey), 335
- Silastic containing d-norgestrel, IUD, 295
- Silastic device, vaginal, containing 15(S)-15 methyl $\text{PGF}_2\alpha$
methyl ester for second trimester abortion, 175
- Silastic implant,
norethindrone, local tissue response, 39
norethindrone acetate, serum concentration of nore-
thindrone, 473
- Single administration, vaginal suppository for interruption
of second trimester pregnancy, 129
- Social factors, post-coital contraceptive users, 445
- Spectroscopic investigation, copper IUD corrosion layer, 93
- Sperm fertility, effect of cyproterone acetate (rat), 429

- Sperm immobilizing antibody (rabbit), 15
- Spermatogenesis,
 - effect of anabolic steroid, metandienone, 151
 - effect of medroxyprogesterone acetate and testosterone enanthate, 649, 669
 - effect of medroxyprogesterone acetate and testosterone propionate, 649
 - inhibition by medroxyprogesterone acetate and testosterone enanthate, 627
- Spermatozoa,
 - effect of hydroxypropylmethylcellulose, 233
 - selective binding of steroids, 163
- Spermicidal effect of hydroxypropylmethylcellulose, 233
- Sponge, collagen, for intravaginal contraception, 693
- Sterilization,
 - effect of vasectomy on hepatic mixed function mono-oxygenase enzymes (rat), 535
 - interval vaginal tubal ligation, use of the Culdo-speculum, 225
 - reversibility of tubal ring technique (rabbit), 505
- Steroids,
 - effect on corpus luteum function (sheep), 53
 - selective binding by spermatozoa, 163
- Subdermal implants, R-2323 (monkey), 335
- Sulphydryl group, level in cervical mucus, 543
- Synthetic estrogens, metabolic fate after exposure to oral contraceptives (baboon), 307
- Techniques for IUD insertion, modified method, 75
- Termination of pregnancy, contraceptive practice before and after, 347
- Tissue response, silastic implant containing norethindrone, 39
- Trace metals, levels in cervical mucus, 543
- Trend in preference of contraceptive methods, 553
- Tubal ligation, use of the Culdospeculum, 225
- Tubal ring sterilization, reversibility (rabbit), 505
- Uniform dosage levels,
 - effect of medroxyprogesterone acetate and testosterone enanthate on spermatogenesis, 649
 - effect of medroxyprogesterone acetate and testosterone propionate on spermatogenesis, 649
- Unwanted births, contraceptive use at time of conception, 705
- Use-effectiveness, injectable norethisterone oenanthate and medroxyprogesterone acetate, 513
- Uterus and its fluid, fibrinolytic activity with copper IUD (rabbit), 215
- Vacuum aspiration, use of 15(S) 15 methyl PGF₂ α methyl ester vaginal suppositories for dilatation of cervix, 285

CONTRACEPTION

- Vaginal silastic device, 15(S)-15 methyl $\text{PGF}_2\alpha$ methyl ester, second trimester abortion, 175
- Vaginal suppository,
 - 15-methyl $\text{PGF}_2\alpha$ methyl ester for interruption of pregnancy, 129
 - 15(S) 15 methyl $\text{PGF}_2\alpha$ methyl ester, dilatation of cervix, 285
- Vasectomy, effect on hepatic mixed function monooxygenase enzymes (rat), 535
- Vulvovaginal candidiasis, cure rate of oral contraceptive users and non-users, 355
- Zinc, level in cervical mucus, 543

INDEX TO VOLUME 16

AUTHOR INDEX

- Abdel Gawad, A.H., 469
 Abd-El-Hay, M.M., 409
 Agarwal, N., 243, 383
 Aitken, R.J., 227
 Alapiessa, U., 51
 Allen, G.O., 541
 Aubert, J.M., 557
 Aznar, R., 79, 287, 299
 Barnard, G., 269
 Basu, R., 533
 Batra, S., 217
 Berger, I., 39
 Bigelow, B., 417
 Boria, M.C., 557
 Brenner, P.F., 625
 Brunk, U., 89
 Buchanan, G.C., 351
 Bye, P.G., 591
 Bygdeman, M., 167, 175
 Chang, M.C., 59
 Charumilind, P., 67
 Chatterjee, A., 11, 533
 Chatterjee, T.K., 327
 Chumnijarakij, T., 67
 Cohen, J., 581
 Collins, W., 269
 Croxatto, H.B., 155
 Czerwinski, C.L., 563
 Devi, P.K., 175
 Diaz, S., 155
 Dileepkumar, 487
 Dogs, G., 199
 Dominguez, R., 299
 Ebert, K.M., 149
 Edson, M., 563
 Edström, K., 183
 Elder, M., 591
 El Sahwi, M., 469
 El Sahwi, S., 437, 453, 469
 Erkkola, R., 569, 575
 Fotherby, K., 591
 Fotiou, S., 167
 Fox, K.A., 149
 Gallegos, A.J., 79, 287, 299
 Ganguly, M., 417
 Garzón, P., 79
 Goldzieher, J.W., 257
 Gomez-Rogers, C., 313
 Grech, E.S., 175, 327
 Gréen, K., 167
 Grossman, R.A., 67
 Grudzinskas, J.G., 605
 Grundsell, H., 217
 Gustavii, B., 89
 Hafez, E.S.E., 499
 Hagenfeldt, K., 183
 Hahn, D.W., 541
 Hanff, G., 89
 Harper, M.J.K., 227
 Haspels, A.A., 175
 Hawkins, D.F., 339
 Helton, E.D., 257
 Hingorani, V., 243, 383, 487
 Hirvonen, E., 51
 Hohman, W.R., 507
 Howard, G., 591
 Hsu, Y.-C., 417
 Hümpel, M., 199
 Ilancheran, A., 377
 Jackanicz, T.M., 125
 Jain, A.K., 487
 Jha, P., 487
 Johannisson, E., 183
 Johansson, E.D.B., 115, 125, 137, 615
 Johnsonbaugh, R.E., 563
 Joyce, D.N., 339
 Karim, S.M.M., 377
 Keown, K.K., Jr., 1
 Kinoshita, K., 167
 Kinra, G., 243
 Laakso, L., 575
 Landgren, B.-M., 183
 Lau, I.F., 59
 Laumas, K.R., 383, 487
 Laumas, V., 487

CONTRACEPTION

INDEX TO VOLUME 16

AUTHOR INDEX (CONTINUED)

- Lewis, S.B., 351
 Liukko, P., 569, 575
 Lucero, S., 313
 Lundström, V., 167
 Macaulay, L., 507
 McEwan, J.A., 339
 McGuire, J.L., 541
 Meltz, M.L., 257
 Mercado, E., 287, 299
 Mishell, D.R., Jr., 625
 Moore, D.E., 625
 Moyer, D.L., 39, 437, 453, 507
 Mroueh, A.M., 19
 Nash, H.A., 125
 Neuwirth, R.S., 581
 Newton, J.R., 269, 523
 Ngai, H.K., 637
 Niles, L., 327
 Nilsson, S., 615
 Nummi, S., 51
 Nyberg, R., 175
 Nygren, K.-G., 615
 Olivera, E., 79
 Page, M.A., 625
 Pageaut, G., 357
 Pal, A.K., 11
 Pavez, M., 155
 Peluso, J.P., 499
 Pizarro, E., 313
 Prasad, R.N.V., 377
 Pronk, J.C., 29
 Purandare, V.N., 175
 Quinteros, E., 155
 Rahman, S.A., 487
 Ranta, T., 51
 Rao, B., 377
 Ratnam, S.S., 377
 Reading, A.E., 523
 Reame, N.E., 409
 Reboud, S., 357
 Reyniak, J.V., 557
 Richart, R.M., 581
 Rietz, S., 199
 Robertson, D.N., 155
 Rosado, A., 287, 299
 Rowe, P.J., 175, 313
 Roy, S., 625
 Saksena, S.K., 59
 Saleh, F.M., 399, 409, 469
 Saxena, B.N., 605
 Sen, K., 11
 Seth, U., 383
 Shaw, S.T., Jr., 283, 507
 Shrimanker, K., 591, 605
 Simmons, R., 257
 Sjöberg, N.-O., 217
 Smith, K.D., 261
 Speck, U., 199
 Steinberger, E., 261
 Stevenson, T., 581
 Stone, M.L., 557
 Takkar, D., 487
 Thompson, R.S., 39
 Topozada, H.K., 469
 Tothill, A.U., 339
 Tredway, D.R., 351
 van der Steeg, H.J., 29
 Victor, A., 115, 125, 137
 Vihko, R., 51
 Viinikka, L., 51
 Virkkunen, P., 51
 Wagner, D., 581
 Wan, L.S., 417
 Weiss, Chr., 199
 Wendt, H., 199
 Wens, M. de los Angeles, 287
 Wilson, E.W., 367
 Wong, P.Y.D., 637
 Wong, Y.M., 377
 Yadawa, H.S., 383
 Yeung, C.H., 637
 Ylikorkala, O., 51
 Zinser, H., 581

INDEX TO VOLUME 16

SUBJECT INDEX

- Abortion,
 - high risk pregnancy, use of prostaglandins, 243
 - 15(S)15-methyl prostaglandin F₂ α methyl ester
 - suppository, 327
 - vaginal administration of 16,16-dimethyl-PGE₂ vs.
 - vacuum aspiration, 167
- Acceptors of contraceptives, study of pills and IUDs, 67
- Anti-implantation action, medicated intrauterine delivery
 - system (rabbit), 39
- Automatic extraction, method for measuring menstrual blood
 - loss, 269
- Biochemical changes in endometrium induced by progesterone-
 - releasing device, 183
- BL141 (3-hydroxy-6 α -methyl-17 acetoxo progesterone)
- BL141, topographical response and epithelial abnormalities
 - of cervix (mouse), 357
- Blastocyst, inhibiting early luteotrophic activity, 227
- Bleeding governs self-administered contraceptive rings, 137
- Blood loss,
 - menstrual, measurement, 283
 - menstrual, rapid method for measurement, 269
- Carbohydrate, protein-bound, effect of long-acting progesta-
 - tional contraceptive therapy, 399
- Cauda epididymis, effect of α -chlorohydrin on transport
 - processes (rat), 637
- Cellular environment, uterine, association with IUDs, 469
- Cervix, topographical response and epithelial abnormalities
 - after administration of progestational
 - compounds (mouse), 357
- α -Chlorohydrin (3-chloro-1,2-propanediol)
- α -Chlorohydrin, effect on transport processes of cauda
 - epididymides (rat), 637
- Chorionic gonadotropin, use in pregnancy wastage studies
 - (rat), 11
- Clinical performance, contraceptive vaginal ring containing
 - d-norgestrel, 625
- Clinical trial with subdermal implants of R-2323, 155
- Clip sterilization failures, 19
- Collagen band, vaginal delivery system for contraceptive
 - steroids, 125
- Comparative study, progesterone T and copper 7 IUDs, 313
- Contraceptive, male, testosterone enanthate, 261
- Contraceptive acceptors, study of pills and IUDs, 67
- Contraceptive experience, GR2/1159, new progestogen, 339
- Contraceptive ring, self-administered treatment governed
 - by bleeding, 137

CONTRACEPTION

- Contraceptive sponges, intravaginal, 1
- Contraceptive steroids,
 - levels in breast milk and plasma of lactating women, 605, 615
 - delivered vaginally by collagen bands, 125
- Contraceptive vaginal rings, d-norgestrel, clinical performance and endocrine profile, 625
- Copper, effect on lactic dehydrogenase isoenzymes in endometrium, 367
- Copper 7 and progesterone T IUDs, comparative study, 313
- Copper 7 IUD, effect on hCG levels, 557
- Copper IUD, effect on lysosomal enzymes in endometrium, 299
- Copper T, effect on ectopic pregnancy, 569
- Copper T IUD, study of uterine environment, 469
- Cultured cells, effect of rivanol, 89
- Cyclic nucleotides, effect on induction of implantation (rat), 149
- Cyproterone acetate and ethinyloestradiol, intraindividual comparison of pharmacokinetic parameters, 199
- Cytochemical study, effect of rivanol, 89
- Dalkon shield, effect on ectopic pregnancy, 569
- Depot-medroxyprogesterone acetate,
 - liver function tests, 409
 - serum protein-bound carbohydrate and seromucoid levels, 399
- Differential effects of PGE₂ during pregnancy (rat), 533
- Dihydrotestosterone, effect of vasectomy, 563
- 16,16-Dimethyl-PGE₂ vaginal administration vs. vacuum aspiration, 167
- Ectopic pregnancy,
 - effect of IUDs, 569
 - use of low-dose progestogens, 575
 - use of lynestrenol, 575
 - use of norethisterone, 575
 - use of d-norgestrel, 575
- Electron microscopic study, vascular defects in endometrium by IUDs, 507
- Embryotoxic activity (rabbit),
 - endometrial cells, 437
 - leukocytes, 437
 - liver cells, 437
 - macrophages, 437
 - red blood cells, 437
 - thyroid cells, 437
- Embryotoxic effect (rabbit, mouse),
 - endometrial homogenate, 453
 - liver homogenate, 453
 - macrophage homogenate, 453
 - polymorphonuclear leukocyte homogenate, 453

- Emetine hydrochloride, use in medicated intrauterine delivery system (rabbit), 39
- Endocrine profile, contraceptive vaginal ring containing d-norgestrel, 625
- Endometrial cells, embryotoxic activity (rabbit), 437
- Endometrial homogenate, embryotoxic effect (rabbit, mouse), 453
- Endometrium,
 - biochemical and morphological changes induced by progesterone-releasing device, 183
 - effect of copper IUD on lysosomal enzymes, 299
 - effect of copper on lactic dehydrogenase isoenzymes, 367
 - effect of inert IUD on lysosomal enzymes, 299
 - effect of progesterone-releasing IUD, 417
 - effect of progesterone-releasing T IUD, 299
 - estradiol-17 β and progesterone concentrations during menstrual cycle, 217
 - interfering with progesterone receptors, 227
 - progesterone metabolism by proliferative and secretory endometria, 79
 - subcellular distribution of lysosomal enzymes, 287
 - vascular defects caused by IUDs, 507
- Epididymis, cauda, effect of α -chlorohydrin on transport processes (rat), 637
- Epithelial abnormalities of cervix, administration of progestational compounds (mouse), 357
- Estradiol cyclopentylpropionate pregnancy wastage, reversal studies (rat), 11
- Estradiol-17 β , effect of norethindrone acetate, 487
- Estradiol-17 β concentration in endometrium during menstrual cycle, 217
- Ethinylloestradiol + d-norgestrel, effect on serum lipoproteins and skinfold thickness, 29
- Ethynylestradiol, metabolites produced by incubation of liver tissue, 257
- Extraction, automatic, method for measuring menstrual blood loss, 269
- Failures of clip sterilization, 19
- Fallopian tube, blind single application delivery system for occlusion, 581
- Fluorescence microscopic study, effect of rivanol, 89
- Follicle stimulating hormone,
 - effect of norethindrone acetate, 487
 - effect of norethisterone oenanthate, 591
 - effect of vasectomy, 563
- FSH (follicle stimulating hormone)
- Gonadotrophin levels, effect of norethisterone oenanthate, 591

CONTRACEPTION

- GR2/1159 (17 α -acetoxy-6 β ,11 β -dichloro-19-norpregna-4,6-diene-3,20-dione)
- GR2/1159, contraceptive experience with new progestogen, 339
- hCG (human chorionic gonadotropin)
- Hemoclip sterilization failures, 19
- High risk pregnancy, use of prostaglandins for induction of abortions, 243
- Historical perspectives, intravaginal contraceptive sponges, 1
- Hormone levels, effect of vasectomy, 563
- Human chorionic gonadotropin, effect of IUDs, 557
- Implant, subdermal,
 clinical trial with R-2323, 155
 effect of norethindrone acetate on lactation, 383
 norethindrone acetate, 487
- Implantation,
 induction by cyclic nucleotides (rat), 149
 new methods for regulation, 227
- Indomethacin (1-(p-chlorobenzoyl)-5-methoxy-2-methylindol-3-acetic acid)
- Indomethacin and PGE₂, effect on pregnancy (rat), 533
- Induction of implantation by cyclic nucleotides (rat), 149
- Inhibition of early luteotrophic activity of blastocyst, 227
- Inhibition of implantation, 227
- Insertion of IUDs, effect of psychological preparation on pain, 523
- Interference of progesterone receptors in endometrium, 227
- Intraindividual comparison of pharmacokinetic parameters,
 cyproterone acetate, 199
 lynestrenol, 199
 d-norgestrel, 199
- Intrauterine delivery system, use of emetine hydrochloride (rabbit), 39
- Intrauterine device,
 assessment of hCG during luteal phase, 557
 comparative study of progesterone T and copper 7, 313
 copper,
 comparative study with progesterone T, 313
 effect on ectopic pregnancy, 569
 effect on hCG levels, 557
 effect on lactic dehydrogenase isoenzymes in endometrium, 367
 effect on lysosomal enzymes in endometrium, 299
 study of uterine environment, 469
 effect on ectopic pregnancy, 569
 effect on lysosomal enzymes in endometrium, 299
 Lippes loop, study of uterine environment, 469
 progesterone-releasing,
 biochemical and morphological changes in endometrium, 183
 comparative study with copper 7, 313

- Intrauterine device,
 - progesterone-releasing,
 - effect on lysosomal enzymes in endometrium, 299
 - effect on menstrual pattern, ovarian steroids and endometrium, 417
 - psychological preparation at insertion, 523
 - study of new contraceptive acceptors, 67
 - study of uterine environment, 469
 - vascular defects in endometrium, 507
- Intravaginal contraceptive sponges, historical perspectives, 1
- Intravaginal PGF₂ α , incorporated in silastic-polyvinyl-pyrrolidone tube (rabbit), 59
- Intravaginal ring,
 - medroxyprogesterone acetate, 115
 - d-norgestrel, 115, 137
 - d-norgestrel + estradiol benzoate, 125
- IUD (intrauterine device)
- Lactating women,
 - level of contraceptive steroids in breast milk and plasma, 605
 - level of megestrol acetate in plasma and milk, 615
- Lactation, effect of norethindrone acetate, 383
- Lactic dehydrogenase isoenzymes, endometrium, effect of copper, 367
- Leukocyte homogenate, embryotoxic effect (rabbit, mouse), 453
- LH (luteinizing hormone)
- Lipoproteins, serum, effect of oral contraceptive, 29
- Lippes loop,
 - effect on ectopic pregnancy, 569
 - effect on hCG levels, 557
 - study of uterine environment, 469
- Liquids, distribution in fallopian tube when delivered blindly, 581
- Liver cells, embryotoxic activity (rabbit), 437
- Liver function tests, depot-medroxyprogesterone acetate and norethisterone oenanthate, 409
- Liver homogenate, embryotoxic effect (rabbit, mouse), 453
- Liver tissue incubation, conjugated metabolites of ethynyl-estradiol, 257
- Low-dose progestagen, Org 2969, effect on ovulation inhibition, 51
- Low-dose progestogen, effect on ectopic pregnancy, 575
- Luteal function,
 - disruption with oestradiol-17 β , 227
 - disruption with prostaglandins, 227
- Luteal phase, effect of IUDs on hCG levels, 557
- Luteinizing hormone,
 - effect of norethindrone acetate, 487
 - effect of norethisterone oenanthate, 591
 - effect of d-norgestrel (monkey), 499
 - effect of vasectomy, 563

CONTRACEPTION

- Luteotrophic activity of blastocyst, inhibition 227
- Lynestrenol, occurrence of ectopic pregnancy, 575
- Lynestrenol + ethinylloestradiol, intraindividual comparison of pharmacokinetic parameters, 199
- Lysosomal enzymes, subcellular distribution in endometrium, 287, 299
- Lysosomal enzymes in endometrium,
 - effect of copper IUD, 299
 - effect of inert IUD, 299
 - effect of progesterone-releasing T IUD, 299
- Macrophage, embryotoxic activity (rabbit), 437
- Macrophage homogenate, embryotoxic effect (rabbit, mouse), 453
- Male contraceptive, testosterone enanthate, 261
- Male with pituitary microadenoma, oral contraceptive exposure, case report, 351
- Measuring menstrual blood loss, automatic extraction, 269
- Medicated intrauterine delivery system, anti-implantation action (rabbit), 39
- Medroxyprogesterone acetate, depot,
 - liver function tests, 409
 - serum protein-bound carbohydrate and seromucoid levels, 399
- Medroxyprogesterone acetate, level in breast milk and plasma, 605
- Megestrol acetate + ethinyl estradiol, level in plasma and milk, 615
- Menstrual blood loss,
 - measurement, 283
 - rapid method for measurement, 269
- Menstrual cycle,
 - distribution of lysosomal enzymes in endometrium, 287
 - estradiol-17 β and progesterone concentrations in endometrium, 217
- Menstrual induction, use of 16-phenoxy- ω -tetranor PGE₂ methylsulfonylamide, 377
- Menstrual pattern, effect of progesterone-releasing IUD, 417
- Metabolism, progesterone, by proliferative and secretory endometria, 79
- Metabolites of ethinylestradiol, incubation of liver tissue, 257
- Methods for regulation of implantation, 227
- 15-Methyl-PGF₂ α , use for abortions in high risk pregnancy, 243
- 15-Methyl PGF₂ α methyl ester, repeated vaginal administration, 175
- 15(S)15-Methyl PGF₂ α methyl ester, vaginal administration for induction of abortion, 327
- Methylcyanoacrylate, delivery to fallopian tubes blindly, 581

- Milk,
 - components, effect of norethindrone acetate, 383
 - level of medroxyprogesterone acetate, 605
 - level of megestrol acetate, 615
 - level of norethisterone, 605
 - level of d-norgestrel, 605
- Morphological changes in endometrium induced by progesterone-releasing device, 183
- New contraceptive acceptors, study of pills and IUDs, 67
- Norethindrone acetate,
 - effect on FSH, LH, progesterone and estradiol-17 β , 487
 - effect on lactation, 383
 - silastic implant D, 487
- Norethisterone,
 - effect of norethisterone oenanthate, 591
 - level in breast milk and plasma, 605
 - occurrence of ectopic pregnancy, 575
- Norethisterone oenanthate,
 - effect on serum gonadotrophin levels, 591
 - liver function tests, 409
 - serum level, 591
 - serum protein-bound carbohydrate and seromucoid levels, 399
- Norethynodrel, effect on topographical response and epithelium of cervix (mouse), 357
- Norgestimate (ORF 10131; d-13 β -ethyl-17 α -ethynyl-17 β -acetoxy-gon-4-en-3-one oxime)
- Norgestimate, pharmacological profile (rabbit, rat), 541
- d-Norgestrel,
 - contraceptive vaginal ring, clinical performance and endocrine profile, 625
 - effect on LH levels (monkey), 499
 - effect on ovulation (monkey), 499
 - occurrence of ectopic pregnancy, 575
 - relation to sex hormone binding globulin, 115
- d-Norgestrel + estradiol benzoate, collagen band vaginal delivery system, 125
- d-Norgestrel + ethinyloestradiol,
 - intraindividual comparison of pharmacokinetic parameters, 199
 - level in breast milk and plasma, 605
- Normal menstrual cycle, distribution of lysosomal enzymes in endometrium, 287
- Nucleotides, cyclic, effect on induction of implantation (rat), 149
- Oestradiol-17 β , disruption of luteal function, 227
- Oral contraceptive,
 - ethinyloestradiol + d-norgestrel, 29
 - experience with GR2/1159, 339
 - low-dose progestogens, effect on ectopic pregnancy, 575

CONTRACEPTION

- Oral contraceptives,
 - norgestimate + ethinyl estradiol (rabbit, rat), 541
 - Org 2969, 51
 - study of new contraceptive acceptors, 67
- Oral contraceptive exposure, male with pituitary micro-
adnoma, case report, 351
- Org 2969 (13-ethyl-11-methylene-18,19-dinor-17 α -pregn-4-
en-20-yn-17-ol)
- Org 2969, low-dose, ovulation inhibition, 51
- Ovarian steroids, effect of progesterone-releasing IUD,
417
- Ovulation, effect of d-norgestrel (monkey), 499
- Ovulation inhibition, effect of Org 2969, 51
- Pain at IUD insertion, effect of psychological preparation,
523
- PGE₂ (prostaglandin E₂)
- PGF₂ α (prostaglandin F₂ α)
- Pharmacokinetic parameters,
 - cyproterone acetate, 199
 - lynestrenol, 199
 - d-norgestrel, 199
- Pharmacological profile, norgestimate (rabbit, rat), 541
- 16-Phenoxy- ω -tetranor PGE₂ methylsulfonylamide, use in
menstrual induction, 377
- Pituitary microadenoma, oral contraceptive exposure in a
male, case report, 351
- Plasma levels of d-norgestrel, relation to sex hormone
binding globulin, 115
- Polymorphonuclear leukocyte, embryotoxic activity (rabbit),
437
- Polymorphonuclear leukocyte homogenate, embryotoxic effect
(rabbit, mouse), 453
- Pregnancy,
 - ectopic,
 - effect of IUDs, 569
 - use of low-dose progestogens, 575
 - differential effects of PGE₂ (rat), 533
 - high risk, use of prostaglandins for induction of
abortions, 243
- Pregnancy termination,
 - PGF₂ α in silastic-polyvinyl-pyrrolidone tube (rabbit),
59
 - 16-phenoxy- ω -tetranor PGE₂ methylsulfonylamide, 377
 - repeated vaginal administration of 15-methyl PGF₂ α
methyl ester, 175
- Pregnancy wastage by estradiol cyclopentylpropionate, reversal
studies (rat), 11
- Progestagen, low-dose Org 2969, effect on ovulation inhibition,
51
- Progestational compounds, topographical response and epi-
thelial abnormalities of cervix (mouse), 357

- Progestational contraceptive therapy,
 - liver function tests, 409
 - serum protein-bound carbohydrate and seromuroid levels, 399
- Progesterone,
 - concentration in endometrium during menstrual cycle, 217
 - effect of norethindrone acetate, 487
 - topographical response and epithelial abnormalities of cervix (mouse), 357
- Progesterone and PGE₂, effect on pregnancy (rat), 533
- Progesterone metabolism, proliferative and secretory endometria, 79
- Progesterone receptors in endometrium, interference, 227
- Progesterone T and copper 7 IUDs, comparative study, 313
- Progesterone-releasing IUD,
 - biochemical and morphological changes in endometrium, 183
 - effect on endometrium, 417
 - effect on menstrual pattern, 417
 - effect on ovarian steroids, 417
- Progesterone-releasing T IUD, effect on lysosomal enzymes in endometrium, 299
- Progestin, norgestimate, pharmacological profile (rabbit, rat), 541
- Progestogen, low-dose, effect on ectopic pregnancy, 575
- Progestogen contraception, experience with GR2/1159, 339
- Proliferative endometria, progesterone metabolism, 79
- Prostaglandin E₂,
 - differential effects during pregnancy (rat), 533
 - 16-phenoxy- ω -tetranor-PGE₂ methylsulfonylamide, 377
 - vaginal administration of 16,16-dimethyl-PGE₂, 167
- Prostaglandin F_{2 α} ,
 - disruption of luteal function, 227
 - repeated vaginal administration of 15-methyl PGF_{2 α} methyl ester, 175
 - 15(S)15-methyl prostaglandin F_{2 α} methyl ester, 327
 - silastic-polyvinyl-pyrrolidone tube (rabbit), 59
 - use for abortions in high risk pregnancy, 243
- Protein-bound carbohydrate level, long-acting progestational contraceptive therapy, 399
- Psychological preparation, effect on pain at IUD insertion, 523
- R-2323 (13 β -ethyl-17 α -ethynyl-17-hydroxygona-4,9,11-triene-3-one)
 - subdermal implants, clinical trial, 155
- Red blood cells, embryotoxic activity (rabbit), 437
- Regulation of implantation, new methods, 227
- Repeated vaginal administration, 15-methyl PGF_{2 α} methyl ester, 175

CONTRACEPTION

- Reserpine, use in pregnancy wastage studies (rat), 11
- Reversible male contraceptive, testosterone enanthate, 261
- Rivanol (6,9-diamino-2-oxethyl acridine lactate)
- Rivanol, alterations of cultured cells, 89
- Scanning electron microscopic study, effect of rivanol, 89
- Secretory endometria, progesterone metabolism, 79
- Self-administered treatment governed by bleeding, contraceptive rings, 137
- Seromucoid level, long-acting progestational contraceptive therapy, 399
- Serum lipoproteins, effect of oral contraceptive, 29
- Sex hormone binding globulin, effects of d-norgestrel, 115
- Silastic-polyvinyl-pyrrolidone tube with $\text{PGF}_2\alpha$, termination of pregnancy (rabbit), 59
- Single Application Fertility Regulating device, use in delivery of adhesive to fallopian tubes, 581
- Skinfold thickness, effect of oral contraceptive, 29
- Sponges, intravaginal contraceptive, 1
- Sterilization, hemoclips, 19
- Subcellular distribution, lysosomal enzymes in endometrium, 287, 299
- Subdermal implant, clinical trial with R-2323, 155
- Subdermal silastic implant containing norethindrone acetate, effect on lactation, 383
- Subdermal silastic implant D releasing norethindrone acetate, 487
- Termination of pregnancy,
 - $\text{PGF}_2\alpha$ in silastic-polyvinyl-pyrrolidone tube (rabbit), 59
 - 16-phenoxy- ω -tetranor PGE_2 methylsulfonylamide, 377
 - repeated vaginal administration of 15-methyl $\text{PGF}_2\alpha$ methyl ester, 175
- Testosterone, effect of vasectomy, 563
- Testosterone enanthate, possible reversible male contraceptive, 261
- Thyroid cells, embryotoxic activity (rabbit), 437
- Topographical response of cervix, administration of progestational compounds (mouse), 357
- Transport process, effect of α -chlorohydrin in cauda epididymides (rat), 637
- Uterine environment, association with IUDs, 469
- Vacuum aspiration vs. vaginal administration of 16,16-dimethyl- PGE_2 , 167
- Vaginal delivery system for contraceptive steroids, collagen bands, 125
- Vaginal suppository,
 - 16,16-dimethyl- PGE_2
 - 15-methyl $\text{PGF}_2\alpha$ methyl ester, 175
 - 15(S)15-methyl prostaglandin $\text{F}_2\alpha$ methyl ester, 327

CONTRACEPTION

- Variability in conjugates of ethynylestradiol, incubation
of liver tissue, 257
- Vascular defects in endometrium, IUDs, 507
- Vasectomy, serum hormone levels, 563
- World Health Organization Task Force on Use of Prostaglandins
for Regulation of Fertility, 175

the book is a welcome addition to the literature on the history of the book. It is a well-written, well-organized, and well-illustrated work that will be of interest to a wide range of readers.

The book is a well-written, well-organized, and well-illustrated work that will be of interest to a wide range of readers. It is a welcome addition to the literature on the history of the book.

The book is a well-written, well-organized, and well-illustrated work that will be of interest to a wide range of readers. It is a welcome addition to the literature on the history of the book.

The book is a well-written, well-organized, and well-illustrated work that will be of interest to a wide range of readers. It is a welcome addition to the literature on the history of the book.

The book is a well-written, well-organized, and well-illustrated work that will be of interest to a wide range of readers. It is a welcome addition to the literature on the history of the book.

The book is a well-written, well-organized, and well-illustrated work that will be of interest to a wide range of readers. It is a welcome addition to the literature on the history of the book.

The book is a well-written, well-organized, and well-illustrated work that will be of interest to a wide range of readers. It is a welcome addition to the literature on the history of the book.

The book is a well-written, well-organized, and well-illustrated work that will be of interest to a wide range of readers. It is a welcome addition to the literature on the history of the book.

The book is a well-written, well-organized, and well-illustrated work that will be of interest to a wide range of readers. It is a welcome addition to the literature on the history of the book.

The book is a well-written, well-organized, and well-illustrated work that will be of interest to a wide range of readers. It is a welcome addition to the literature on the history of the book.

The book is a well-written, well-organized, and well-illustrated work that will be of interest to a wide range of readers. It is a welcome addition to the literature on the history of the book.

The book is a well-written, well-organized, and well-illustrated work that will be of interest to a wide range of readers. It is a welcome addition to the literature on the history of the book.

